AUTHOR=Abo-Neima Sahar E. , Ahmed Abdelhamid A. , El-Sheekh Mostafa , Makhlof Mofida E. M. 

TITLE=Polycladia myrica-based delivery of selenium nanoparticles in combination with radiotherapy induces potent in vitro antiviral and in vivo anticancer activities against Ehrlich ascites tumor

JOURNAL=Frontiers in Molecular Biosciences

VOLUME=Volume 10 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1120422

DOI=10.3389/fmolb.2023.1120422

ISSN=2296-889X

ABSTRACT=Polycladia SeNPs (PoSeNPS) with sizes ranging between 17.48 – 23.01nm and 0.46±0.07& 0.08±0.01 selenium mass and atom%, respectively, were synthesized in this work using Polycladia myrica aqueous extract and characterized using seven parameters, SEM, TEM, UV spectra, Zeta potential, EDX, X-ray diffraction, and FTIR, then examined for their anticancer potentiality in vitro with maximum inhibition 80.57%, 73% and IC50=14.86 µg/mL, 50mg/mL against HCT-116 and  EAC cell lines respectively. Polycladia SeNPs in vivo alone and in combination with laser therapy of power 2mw showed a potent therapy effect against Ehrlich ascites carcinoma (EAC). It was concluded that Se-NPs have low toxicity, high effectiveness as a photothermal agent for cancer therapy, and show promising applications for future biomedical fields. The combined therapy shows a very high significant decrease in tumor volume, massive tumor cell necrosis, shrinking, and disappearance. It also shows improvement in liver TEM, histology, kidney function (urea and creatinine), and liver enzymes (ALT and AST).